Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons

@article{Chitwood2013TopicalAI,
  title={Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons},
  author={K. Chitwood and J. Etzkorn and George F. Cohen},
  journal={Dermatologic Surgery},
  year={2013},
  volume={39},
  pages={1306–1316}
}
Background Topical chemotherapy, topical immunomodulators, or intralesional chemotherapy may be used to treat nonmelanoma skin cancer (NMSC). Objectives To review the cost and efficacy of topical and intralesional therapies for NMSC. Methods Literature search assessing the efficacy of NMSC treatment with topical imiquimod, topical 5‐flourouracil (5FU) intralesional 5FU, methotrexate, bleomycin, and interferon (IFN). Single‐lesion case reports were excluded. Aggregate cure rates and the… Expand
Intralesional therapy for the treatment of keratoacanthoma
TLDR
The present study set out to review the current state of the art of the intralesional treatment of KA, which could be cosmetically and functionally a better alternative to surgical removal, while it provides similar outcomes. Expand
Cryosurgery, Intralesional Methotrexate and Imiquimod for Keratoacanthoma: Tuning the Combination
TLDR
It is suggested that the present three modalities combination (one session mild cryosurgery/low dose, 5 mg intralesional methotrexate and 2 weeks once daily imiquimod) is a promising treatment for KA that merits evaluation in further studies. Expand
Immunocryosurgery for Nonmelanoma Skin Cancer: Applications and Practical Tips
TLDR
The efficacy of immunocryosurgery signifies the potential of nonsurgical, combination approaches in the treatment of skin neoplasms and particularly of basal cell carcinoma. Expand
A Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers.
TLDR
The combination of imiquimod/5-fluorouracil/tretinoin with cryotherapy with brief cryotherapy had high clearance rates and was the most effective treatment regimen. Expand
Combination Topical Chemotherapy for the Treatment of an Invasive Cutaneous Squamous Cell Carcinoma
TLDR
Topical combination therapy with imiquimod, 5-FU, and tretinoin with intermittent, brief cryotherapy effectively treated a small, invasive SCC in this select patient who deferred surgery. Expand
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments.
A wide range of treatments is now available for nonmelanoma skin cancer (NMSC), including 5-fluorouracil, ingenol mebutate, imiquimod, diclofenac, photodynamic therapy, methotrexate, cetuximab,Expand
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments.
TLDR
Resistance to the authorized topical treatments for NMSC is reviewed to increase understanding of the nature of each tumor and the biologic features that make it resistant, as well as to facilitate the design of new therapies directed against these tumors. Expand
Intralesional methotrexate in dermatology: Diverse indications and practical considerations
TLDR
Dermatologists should consider using IL‐MTX for a range of recalcitrant cutaneous conditions, particularly for those patients not amenable to surgery or systemic therapy. Expand
Advances in Diagnosis and Treatment of Nonmelanoma Skin Cancer
TLDR
The aim of this review was to present the sensitivity and specificity of new imagingmodalities, the dosing regimen and clearance rates of topical treatments, newer systemic treatment modalities, and discuss developments in the use of radiation as a mode of therapy. Expand
A patient with squamous cell carcinoma in-situ successfully treated with intralesional 5-Fluorouracil and topical trichloroacetic acid
TLDR
A case of SCC successfully treated with intralesional 5-FU and topical Trichloroacetic acid is demonstrated and may be an effective option for patients with SCC who are not eligible for cutaneous surgery. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Intralesional chemotherapy for nonmelanoma skin cancer: a practical review.
TLDR
Responses rates are determined and reasonable treatment guidelines for the treatment of squamous cell carcinoma, keratoacanthoma, and basal cell carcinomas with the most widely available intralesional agents (methotrexate, 5-fluorouracil, bleomycin, and interferon) are suggested. Expand
Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature.
TLDR
Intralesional MTX is a useful nonsurgical therapy for the treatment of KA and a complete blood cell count at baseline and during treatment should be considered to monitor for potential cytopenia. Expand
Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma.
TLDR
Topical application of imiquimod 5% cream might represent an alternative topical treatment to surgery in selected cases of Bowen's disease and invasive SCC. Expand
Treatment of keratoacanthomas with intralesional methotrexate.
TLDR
It is concluded that intralesional methotrexate is a simple and effective modality for the treatment of select keratoacanthomas and may offer greater efficacy, a more rapid response, decreased pain, and lower cost compared with intralsional 5-fluorouracil. Expand
Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
TLDR
At the dosage used, interferon was able to cure only a minority of aggressive BCCs, and the tumor size was reduced by 75%. Expand
Treatment of Bowen's Disease with Topical 5% Imiquimod Cream: Retrospective Study
TLDR
Topical 5% imiquimod cream appears to be clinically beneficial in the treatment of Bowen's disease and should be considered as a treatment option. Expand
Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients.
TLDR
The results demonstrate a high efficacy and a good tolerability of topical treatment of imiquimod 5% cream in BD in TR, which represents a promising new therapeutic modality for BD, especially on exposed areas such as the face and ears. Expand
Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12‐Week Open‐Label Trial
TLDR
Treatment of superficial BCCs with topical imiquimod for 12 weeks produced an excellent clinical response overall, with complete remission maintained after a mean of 23 months of follow-up. Expand
Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report
TLDR
Results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported and suggest that lesions treated with imiquIMod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment. Expand
Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.
TLDR
This trial demonstrates that intralesional interferon is effective in the treatment of small sun-induced squamous cell carcinomas with well-tolerated side effects and a highly acceptable cosmetic result. Expand
...
1
2
3
4
5
...